柴芍六君子汤对ALT<2倍ULN慢性乙型病毒性肝炎患者病毒复制的影响
|
摘要
目的:观察柴芍六君子汤对谷丙转氨酸(alaninetransaminase,ALT)<2倍正常值上限(upper limit of normal,ULN)慢性乙型病毒性肝炎病毒复制的影响。方法:将符合入选标准的300例慢性乙型病毒性肝炎患者随机分成对照组100例和观察组200例。对照组给予逍遥丸口服,观察组给予柴芍六君子汤加减口服,两组疗程均为6个月。治疗期间动态监测乙型肝炎病毒(hepatitis B virus,HBV)-DNA定量及HBsAg定量。结果:观察组治疗至24周时HBV-DNA对数值与治疗前比较,显著下降,且HBV-DNA对数值显著低于同期对照组,差异有统计学意义(P <0. 05)。治疗24周时,观察组HBsAg定量与治疗前比较,显著下降,差异有统计学意义(P <0. 05)。结论:柴芍六君子汤对ALT <2倍ULN慢性乙型病毒性肝炎患者病毒复制具有一定的抑制作用。
Objective: To observe the effect of Chaishao Liujunzi Decoction on ALT < 2 × upper limit of normal( ULN) chronic viral hepatitis B virus replication. Methods: 300 patients with chronic viral hepatitis B who met the inclusion criteria were randomly divided into a control group of 100 patients and an observation group of 200 patients. The control group was given Xiaoyao Pill orally,and the observation group was given modified Chaishao Liujunzi Decoction orally. Both groups were treated for 6 months. Hepatitis B virus( HBV)-DNA quantification and HBsAg quantification were monitored dynamically during treatment. Results: After 24 weeks of treatment,the HBV-DNA pairs in the observation group of Chaishao Liujunzi were significantly decreased compared with those before treatment,and the HBV-DNA pairs were significantly lower than those in the control group at the same period. The difference was statistically significant( P < 0. 05). At 24 weeks of treatment,the HBsAg quantification in the observation group was significantly lower than that before treatment,and the difference was statistically significant( P < 0. 05). Conclusion: Chaishao Liujunzi Decoction has a certain inhibitory effect on viral replication in patients with ALT < 2 × ULN chronic viral hepatitis B.
Objective: To observe the effect of Chaishao Liujunzi Decoction on ALT < 2 × upper limit of normal( ULN) chronic viral hepatitis B virus replication. Methods: 300 patients with chronic viral hepatitis B who met the inclusion criteria were randomly divided into a control group of 100 patients and an observation group of 200 patients. The control group was given Xiaoyao Pill orally,and the observation group was given modified Chaishao Liujunzi Decoction orally. Both groups were treated for 6 months. Hepatitis B virus( HBV)-DNA quantification and HBsAg quantification were monitored dynamically during treatment. Results: After 24 weeks of treatment,the HBV-DNA pairs in the observation group of Chaishao Liujunzi were significantly decreased compared with those before treatment,and the HBV-DNA pairs were significantly lower than those in the control group at the same period. The difference was statistically significant( P < 0. 05). At 24 weeks of treatment,the HBsAg quantification in the observation group was significantly lower than that before treatment,and the difference was statistically significant( P < 0. 05). Conclusion: Chaishao Liujunzi Decoction has a certain inhibitory effect on viral replication in patients with ALT < 2 × ULN chronic viral hepatitis B.
引文
[1]慢性乙型病毒性肝炎特殊患者抗病毒治疗专家委员会.慢性乙型病毒性肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志,2015,31(8):1185-1192.
[2]中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型病毒性肝炎防治指南[J].中国医学前沿杂志,2011,10(1):66-83.
[3]国家食品药品监督管理所.中药新药临床指导原则[M].北京:中国医药科技出版社,2002:208-216.
[4]IIOEJE U H,YANG H I,SU J,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]Gastroenterology,2006,130(3):678-686.
[5]CHEN C J,YANG H I,SU J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA,2006,295(1):65-73.
[6]程晶,唐海鸿,李群,等.补肾解毒健脾冲剂对慢性乙肝病毒携带者HBeAg、HBV-DNA和肝组织学的影响[J].中西医结合肝病杂志,2014,24(4):200-203.
[7]亚太肝病研究学会. 2012年亚太地区慢性乙型病毒性肝炎管理共识[J].中国医学论坛报,2012,38(1):1-2.
[8]薛敬东,李粉萍.名老中医张瑞霞学术思想及临证经验荟萃[M].西安:陕西科学技术出版社,2011.
[9]黄敏,图娅,崔晓兰.慢性乙型病毒性肝炎中医证候规范化与客观化研究进展[J].中医研究,2016,29(7):74-78.
[10]毛果,蔡光先,陈斌. 1868例慢性乙型病毒性肝炎患者中医证候分布特征及与血清病毒学指标的相关性分析[J].湖南中医药大学学报,2014,34(4):24-28.
[11]孙建光,王伟芹,孙玉莉,等.利用数据挖掘技术分析150例ALT <2倍正常值上限的慢性乙型病毒性肝炎中医证候规律[J].中西医结合肝病杂志,2016,26(3):133-136.
[12]李仁国.柴胡有效成分及药理作用分析[J].陕西中医,2013,34(6):750-751.
[13]钟锐.柴芍六君子汤加减方治疗肝纤维化60例[J].环球中医药,2012,5(6):453-455.
[14]张利.白芍的药理作用及现代研究进展[J].中医临床研究,2014,29(6):25-26.
[15]尹燕耀,林云华,宗亚力,等.柴芍六君子汤加减对肝郁脾虚型慢性乙型病毒性肝炎免疫介导发病机制的干预研究[J].辽宁中医杂志,2014,41(11):2394-2396.
[16]田广俊,芮玩珠,陈培琼,等.柴芍六君子汤联合恩替卡韦治疗慢性乙型病毒性肝炎(肝郁脾虚证)30例临床观察[J].广州中医药大学学报,2009,26(3):218-220,224.
[2]中华医学会肝病学分会、中华医学会感染病学分会.慢性乙型病毒性肝炎防治指南[J].中国医学前沿杂志,2011,10(1):66-83.
[3]国家食品药品监督管理所.中药新药临床指导原则[M].北京:中国医药科技出版社,2002:208-216.
[4]IIOEJE U H,YANG H I,SU J,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]Gastroenterology,2006,130(3):678-686.
[5]CHEN C J,YANG H I,SU J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA,2006,295(1):65-73.
[6]程晶,唐海鸿,李群,等.补肾解毒健脾冲剂对慢性乙肝病毒携带者HBeAg、HBV-DNA和肝组织学的影响[J].中西医结合肝病杂志,2014,24(4):200-203.
[7]亚太肝病研究学会. 2012年亚太地区慢性乙型病毒性肝炎管理共识[J].中国医学论坛报,2012,38(1):1-2.
[8]薛敬东,李粉萍.名老中医张瑞霞学术思想及临证经验荟萃[M].西安:陕西科学技术出版社,2011.
[9]黄敏,图娅,崔晓兰.慢性乙型病毒性肝炎中医证候规范化与客观化研究进展[J].中医研究,2016,29(7):74-78.
[10]毛果,蔡光先,陈斌. 1868例慢性乙型病毒性肝炎患者中医证候分布特征及与血清病毒学指标的相关性分析[J].湖南中医药大学学报,2014,34(4):24-28.
[11]孙建光,王伟芹,孙玉莉,等.利用数据挖掘技术分析150例ALT <2倍正常值上限的慢性乙型病毒性肝炎中医证候规律[J].中西医结合肝病杂志,2016,26(3):133-136.
[12]李仁国.柴胡有效成分及药理作用分析[J].陕西中医,2013,34(6):750-751.
[13]钟锐.柴芍六君子汤加减方治疗肝纤维化60例[J].环球中医药,2012,5(6):453-455.
[14]张利.白芍的药理作用及现代研究进展[J].中医临床研究,2014,29(6):25-26.
[15]尹燕耀,林云华,宗亚力,等.柴芍六君子汤加减对肝郁脾虚型慢性乙型病毒性肝炎免疫介导发病机制的干预研究[J].辽宁中医杂志,2014,41(11):2394-2396.
[16]田广俊,芮玩珠,陈培琼,等.柴芍六君子汤联合恩替卡韦治疗慢性乙型病毒性肝炎(肝郁脾虚证)30例临床观察[J].广州中医药大学学报,2009,26(3):218-220,224.